Exeantide in Type 2 Diabetes on Insulin

NCT01154933 on ClinicalTrials.gov · last registry update 2022-10-06

A small phase 2 — 24 participants, against a typical 110. The sponsor logged completion for November 2011. Primary outcome, as filed: Fasting Insulin. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: University at Buffalo
Sponsor type: Other
Enrollment: 24
Started: 2008-04
Primary completion: 2011-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Fasting Insulin

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.